DR. JESUS ALBERTO GOMEZ M.D. NPI 1609873504

NPI Information

  • NPI: 1609873504
  • Provider Name: DR. JESUS ALBERTO GOMEZ, M.D.
  • Classification: Internal Medicine - 207RX0202X
  • Specialization: Medical Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 7848 GATEWAY BLVD E
    EL PASO, TX
    ZIP 79915
  • Phone: (915) 544-6750

Map and Directions

Get Directions

NPI Details

DR. Jesus Alberto Gomez, M.D. is a medical oncology internal medicine in El Paso, TX with 40 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Jesus Alberto Gomez, M.D. NPI is 1609873504. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF TEXAS MEDICAL SCHOOL AT HOUSTON
Graduation Year:1986

The provider's business location address is:

7848 GATEWAY BLVD E
EL PASO, TX
ZIP 79915-815
Phone: (915) 544-6750
Fax: (915) 599-1701

The NPI 1609873504 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
  • Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
  • Injection, denosumab, 1 mg (HCPCS:J0897)
  • Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
  • Insertion of needle into vein for collection of blood sample (HCPCS:36415)
  • Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
  • Injection, fluorouracil, 500 mg (HCPCS:J9190)
  • Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Injection, carboplatin, 50 mg (HCPCS:J9045)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Injection, zoledronic acid, 1 mg (HCPCS:J3489)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Blood test, comprehensive group of blood chemicals (HCPCS:80053)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
  • Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
  • Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
  • Reticulated (young) platelet measurement (HCPCS:85055)
  • Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
  • Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
  • Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
  • Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
  • Automated urinalysis test (HCPCS:81003)
  • Irrigation of implanted venous access drug delivery device (HCPCS:96523)
  • Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
  • Unclassified drugs (HCPCS:J3490)
  • Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
  • Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session (HCPCS:G6015)
  • Lactate dehydrogenase (enzyme) level (HCPCS:83615)
  • Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
  • Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
  • Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev (HCPCS:G6012)
  • Injection of drug or substance into vein (HCPCS:96374)
  • Ct scan of chest with contrast (HCPCS:71260)
  • Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
  • Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)

The enumeration date for this NPI number is 7/7/2005 and was last updated on 3/8/2011.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1174400000XSpecialistH2409TEXASNo
2207RX0202XInternal MedicineMedical OncologyH2409WASHINGTONYes

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.

No. Other Provider Identifier Other Provider Identifier Type Other Provider Identifier State Other Provider Identifier Issuer
1E79360MEDICARE UPINTEXAS
2133951709MEDICAIDTEXAS
300315UMEDICARE ID-TYPE UNSPECIFIEDTEXASGROUP
4TXB103315MEDICARE PINTEXAS
587629551MEDICAIDNEW MEXICO
68A0549MEDICARE ID-TYPE UNSPECIFIEDTEXAS
7133951710MEDICAIDTEXAS
8155014701MEDICAIDTEXAS

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.